ARES · Ares Management Corporation · Stock research

Current Thesis

The leg on offer is unchanged from prior coverage: fee-related earnings compounding on locked-up capital while private credit institutionalises, with Ares increasingly the balance sheet behind AI infrastructure and asset-based finance. Q2 2026 (2026-07-31) delivered the operating half — fee-related earnings $491.1M, after-tax realized income $467.6M ($1.29 per Class A share), AUM $671B at 6/30/26, gross inflows above $36B, record available capital of $170B.

What has changed since the 2026-08-12 update is the price and almost nothing else. The equity closed 2026-08-21 at $141.25 against $136.85 on 2026-08-07, and the reference series now prints a 52-week high of $178.13 rather than the $185.90 earlier coverage cited, putting the drawdown from the trailing high at 20.7%. Every open item is still open. A third-party deal tracker, checked 2026-08-23, still describes the Leonard Green & Partners transaction as "in discussions" — four weeks after the FT report of 2026-07-27. The €3B ($3.4B) European direct-lending secondaries sale disclosed 2026-07-27 has no public clearing price. The $2.2B MedImpact loan Bloomberg reported on 2026-08-05 has no public final pricing.

The narrative is saturated. Six sell-side target actions landed on a single day (2026-08-03); FT, Bloomberg and Axios all covered the name across 2026-07-27/28; ARES appeared in a retail-facing Benzinga listicle ("5 Stocks to Buy Before the Fed's Next Move", 2026-07-20). Since 2026-08-12 the ARES-tagged flow has been sector-level rather than company-level — Jefferies Credit Partners moving its own loans into a new fund (2026-08-19), and two 2026-08-18 opinion pieces on retail exposure to AI-adjacent credit. Broad attention, thin new company-specific news, price a fifth below the trailing high with fee earnings still compounding near 20% year-on-year.

Bullish and bearish views on Ares Management Corporation

The model's bull view on Ares Management Corporation (ARES), in brief: Q2 2026 (2026-07-31): fee-related earnings $491.1M; after-tax realized income $467.6M, $1.29 per Class A share; AUM $671B at 6/30/26 with record available capital of $170B. The bear view: The liquidity sequence predates the August coverage. Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-31): fee-related earnings $491.1M; after-tax realized income $467.6M, $1.29 per Class A share; AUM $671B at 6/30/26 with record available capital of $170B.
• Same print, call coverage: AUM and fee-paying AUM both +17% YoY (roughly $671B and $410B); FRE +20% YoY; management fees above $1B, +14% YoY with no catch-up fees; realized income $522M, +30%.
• Forward pipeline metrics from the 2026-07-31 call: confidentiality agreements signed with sponsors up roughly 35% QoQ, new deals entering the pipeline up roughly 30% QoQ — the earliest observable that origination turns before it reaches fee-paying AUM.
• Credit secondaries volume in H1 2026 already matched all of 2025 per management on the 2026-07-31 call. Ares stands on both sides: seller of $3.4B of European direct-lending LP interests (announced 2026-07-27) and a buyer through its secondaries platform, which the 2025-10-08 ASIS III release put at nearly $34B of secondaries assets across strategies.
• Deployment continued at wide spreads through the redemption headlines: Ares is leading the $2.2B direct loan financing MedImpact Holdings' purchase of Medical Card System, expected to price at a spread of at least eight percentage points over the benchmark (Bloomberg, 2026-08-05).
• Post-print targets set 2026-08-03: RBC Outperform $168, TD Cowen Buy $155, JP Morgan Overweight $153, Oppenheimer Outperform $151 (raised from $140 on 2026-07-17), BMO Market Perform $134 (raised from $128 on 2026-07-13).
• Dividend of $1.35 per Class A/non-voting share declared 2026-07-30, payable 2026-09-30 to holders of record 2026-09-16.

Bear Case

• The liquidity sequence predates the August coverage. Bloomberg, 2026-06-25: an Ares private credit fund capped redemptions after 14% of investors sought to exit. Six weeks later, FT and Benzinga (2026-08-06) reported a flagship private credit vehicle scaled back after valuation pushback, and Bridgepoint moving to offload $1.1B of private credit stakes.
• Credit quality moved the wrong way at the print: Ares flagged an uptick in underperforming investments in Q2, tied in reporting to AI disruption of borrowers (2026-07-29). One quarter is one quarter; the second reading arrives at the Q3 print.
• The top line missed on the consensus construction: Q2 sales $1.018B against a $1.200B estimate (2026-07-31), with adjusted EPS $1.29 merely in line. The revenue line is a poor scorecard for this model, but it is the line index and screen buyers see.
• Two headline options have now carried for four weeks without resolution — Leonard Green (reported 2026-07-27, still listed in discussions on 2026-08-23) and the $3.4B secondaries sale (announced 2026-07-27, unpriced). Optionality that does not resolve decays.
• A Reuters item carried on TradingView is headlined "Ares Management Sells 32.3 Million Common Shares For About $800 Million In August 2026"; the article body is paywalled and the implied ~$24.77 per share is nowhere near where ARES Class A trades, so the security involved is not identified on the public preview. It should not be read as a Class A issuance without the underlying filing, and it is flagged here precisely because the headline shape invites that reading.
• BMO's $134 Market Perform target sits below the 2026-08-21 close of $141.25 — one of six covering shops that raised targets on 2026-08-03 already has the shares above fair value on its own work.

Setup & Price Structure

The 2026-08-21 close of $141.25 sits 20.7% under the 52-week high of $178.13 on the split/dividend-adjusted series, with a three-month price change of +14.7% and RSI(14) at 53.3. That combination — a fifth off the high, a mid-range oscillator, a double-digit three-month advance — describes a stock that has recovered part of a large drawdown and then stopped, not one extending.

The price now sits inside the analyst spread rather than beneath it: above BMO's $134, below Oppenheimer's $151, TD Cowen's $155, JP Morgan's $153 and RBC's $168. The $151–$155 cluster is the level the sell-side effectively marked as the post-Q2 destination on 2026-08-03; it has not been touched since.

Crowding and positioning observables, stated without a verdict: five of six covering brokers raised targets on one day (2026-08-03); the name carried mainstream wire and newspaper coverage across 2026-07-27/28; a retail listicle carried it on 2026-07-20; the ARES-tagged headline flow since 2026-08-12 has been about other people's private credit books (Jefferies, 2026-08-19) and about retail exposure to AI-adjacent credit generally (2026-08-18). No insider transactions surfaced in the filing feed covering this window — absence from a feed is not proof of none. The next scheduled company event is a dividend record date, not a print, so nothing on the calendar forces a repricing before late October.

Catalyst Calendar (next 30 days)

• 2026-09-15 — Series B mandatory convertible preferred record date (payable 2026-10-01).
• 2026-09-16 — Common dividend record date, $1.35 per Class A/non-voting share (payable 2026-09-30). The adjusted price series steps down around the ex-date; the level any thesis is graded against moves with it.
• ~2026-10-28 (est.) — Q3 2026 results. Outside the 30-day window and the first hard grading event on credit quality.

Elapsed catalysts

• Unscheduled (reported 2026-07-27) — Outcome of the Leonard Green & Partners talks. Still listed as in discussions by a third-party tracker checked 2026-08-23. (passed 3d ago)
• Unscheduled (announced 2026-07-27) — Pricing of the €3B/$3.4B European direct-lending secondaries sale (LP interests in the fourth vintage of Ares Capital Europe). (passed 30d ago)
• Unscheduled (reported 2026-08-05) — Final pricing and allocation of the $2.2B MedImpact/Medical Card System loan. (passed 21d ago)

What Would Change Our Mind

The structural break is the post-print recovery being given back. A weekly close below $130 puts the shares under both the 2026-08-07 close of $136.85 and the 2026-08-21 close of $141.25, which would mean the entire response to a print showing $671B of AUM and $36B of inflows has been erased by the credit and liquidity headlines rather than the reverse.

Three non-price conditions would do the same work on the fundamentals. First, a second sequential rise in underperforming investments at the ~2026-10-28 Q3 print, after the uptick disclosed 2026-07-29 — one quarter is noise, two is a trend in the book. Second, Q3 gross inflows landing materially below the $36B Q2 record, or another Ares vehicle gating or resizing after the 2026-06-25 redemption cap; the fee engine is a fundraising engine. Third, the Leonard Green talks lapsing without agreement, which removes an option the equity has carried since 2026-07-27 without ever paying for it.

The upside condition that would force a re-rating of the label: the $3.4B secondaries book clearing at or near carrying value, published, which converts the largest open mark on the direct-lending industry from a rumour into a datapoint.

Correlation Notes

• Ares Capital Corp (ARCC) is the listed public proxy for the same underwriting. Its non-accrual rate is the highest-frequency read on the credit-deterioration risk the manager flagged 2026-07-29, and it reports separately.
• The name trades with the listed alternative-manager complex (BX, KKR, APO, TPG) on rate expectations and on any single-firm credit accident; the 2026-06-25 redemption story and the 2026-08-06 valuation-pushback story both moved as sector news.
• Second-order linkage: private credit is now a funding channel for AI data-centre buildout, so ARES has picked up correlation to AI capex sentiment on both legs — as a lender when spreads widen, and as a narrative beneficiary when the buildout accelerates. The 2026-08-18 pieces on retail exposure to AI-adjacent credit are the popular-press version of that link.
• Read-across risk from affiliate transactions elsewhere in the industry: the Jefferies Credit Partners story of 2026-08-19 (moving its own loans into a new fund) keeps the question of who marks and who buys private loans in the tape, and that question prices every manager at once.